CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the CHAMPION PHOENIX trial The performance of non-invasive tests to rule-in and rule-out significant coronary artery stenosis in patients with stable angina: a meta-analysis focused on post-test disease probability Contemporary use of drug-coated balloons in coronary artery disease: Where are we now? Impact of Artificial Intelligence on Interventional Cardiology: From Decision-Making Aid to Advanced Interventional Procedure Assistance A prospective natural-history study of coronary atherosclerosis The Year in Cardiovascular Medicine 2020: Coronary Intervention Treating Multivessel Coronary Artery Disease in ST-Segment Elevation Myocardial Infarction: Why, How, and When? Comparison of Heart Team vs Interventional Cardiologist Recommendations for the Treatment of Patients With Multivessel Coronary Artery Disease Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia Rotational atherectomy and new-generation drug-eluting stent implantation

Original Research2022 Feb, 79 (6) 562–573

JOURNAL:J Am Coll Cardiol. Article Link

A Score to Assess Mortality After Percutaneous Mitral Valve Repair

S Raposeiras-Roubin , M Adamo , X Freixa et al. Keywords: transcatheter edge-to-edge mitral valve repair; TEER; severe mitral regurgitation; risk stratification; risk predictor

ABSTRACT

BACKGROUND - Risk stratification for transcatheter edge-to-edge mitral valve repair (TEER) is paramount in the decision-making process for treating severe mitral regurgitation (MR).


OBJECTIVES - This study sought to create and validate a user-friendly score (MitraScore) to predict the risk of mortality in patients undergoing TEER.


METHODS - The derivation cohort was based on a multicentric international registry that included 1,119 patients referred for TEER between 2012 and 2020. Score discrimination was assessed using Harrells c-statistic, and the calibration was evaluated with the Gronnesby and Borgan goodness-of-fit test. An external validation was carried out in 725 patients from the GIOTTO registry.


RESULTS - After multivariate analysis, we identified 8 independent predictors of mortality during the follow-up (2.1 ± 1.8 years): age 75 years, anemia, glomerular filtrate rate <60 mL/min/1.73 m2, left ventricular ejection fraction <40%, peripheral artery disease, chronic obstructive pulmonary disease, high diuretic dose, and no therapy with renin-angiotensin system inhibitors. The MitraScore was derived by assigning 1 point to each independent predictor. The c-statistic was 0.70. Per each point of the MitraScore, the relative risk of mortality increased by 55% (HR: 1.55; 95% CI: 1.44-1.67; P < 0.001). The discrimination and calibration for mortality prediction was better than those of EuroSCORE II (c-statistic 0.61) or Society of Thoracic Surgeons score (c-statistic 0.57). The MitraScore maintained adequate performance in the validation cohort (c-statistic 0.66). The score was also predictive for heart failure rehospitalization and was correlated with the probability of clinical improvement.


CONCLUSIONS - The MitraScore is a simple prediction algorithm for the prediction of follow-up mortality in patients treated with TEER.